“Global Biosimilar Drugs market set to grow to $57bn by 2023” says new Visiongain report

17 April 2019
Pharma

Visiongain has published a new pharma report Top 25 Biosimilar Drug Manufacturers 2019: Humira, Remicade, Enbrel, Aranesp, Rituxan, Sandoz, Teva, Hospira, Pfizer, STADA Arzneimittel, Mylan, 3SBio, Qilu Pharmaceutical, Shanghai Fosun Pharmaceutical, Biocon, Dr. Reddy’s Laboratories, Probiomed, Biosidus, Celltrion, LG Life Sciences, Other Companies.

There is an extensive pipeline for biosimilars at the moment, with the main targets being the best-selling biologics who have patent expiry’s coming up. This patent cliff will provide a lot of opportunities for biosimilars manufacturers to gain a larger market share and could see biosimilars being placed into the spotlight as a viable and logical way of diversifying a company’s pharmaceutical portfolio. This will also see more entrants to this market which could see it become more consolidated and competitive in the future.

This report profiled the selected companies: 3SBio, Amega Biotech, Beijing ShuangLu Pharmaceuticals, Biocad, Biocon, Biosidus, Bioton, Celltrion, Dong-A, Dr Reddy’s Laboratories, Intas Biopharmaceutical, LG Life Sciences and other companies.

The lead analyst commented that "The biosimilars landscape will likely to undergo great changes in the future as the market starts to mature. Big pharma companies will enter the market and more companies will start to consolidate to avoid a hostile takeover and to protect their market position. Once more money is invested in researching biosimilars, progress will be made on the technology used, the type of biosimilars they can create and the cost of doing so.

Visiongain predicts the biosimilars landscape will change owing to the arrival of more big-name pharma companies into the biosimilars scene. With an ever-increasing market size, technological advancements and strong R&D pipelines, the biosimilars market is in a great position to continue its rise as one of the key new pharmaceutical sectors. That progress will highlight its ability to benefit companies, healthcare professionals and patients."

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

Read

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

Read

“Top 25 Vaccines market set to grow to $41bn by 2024” says new Visiongain report

There is an increasing focus to identify diseases that currently do not have a vaccine.

20 June 2019

Read

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever